Publications by authors named "Tomoo Ogawa"
Article Synopsis
- Lecanemab is a monoclonal antibody designed to target and reduce harmful amyloid-β aggregates in the brain, specifically for early-stage Alzheimer's disease.
- The drug was tested in international Phase II and Phase III placebo-controlled studies, which included participants from Japan, confirming its safety and efficacy.
- It received accelerated approval in the U.S. in January 2023, followed by full approval in July 2023, and was also approved in Japan for managing early-stage Alzheimer's in September 2023.
Neuroleptic malignant syndrome (NMS) is often considered to be a precipitating factor for diabetic coma, such as a hyperosmolar hyperglycemic state (HHS). The combination of NMS and a systemic illness such as HHS can be difficult to diagnose because NMS may mask the coexisting condition. Although this coexistence is rare, it may be fatal if not detected early.
View Article and Find Full Text PDFThe combined effect against human immunodeficiency virus (HIV) of oxanosine and 2'3'-dideoxyinosine (ddI) has been evaluated by the production of viral particles, the expression of viral antigens on cell surfaces, and the amount of viral genome integrated in the host cells. Oxanosine alone has no effect on HIV replication up to 100 microg/ml, however, in the presence of ddI, oxanosine revealed concentration dependent inhibition against HIV without cytotoxicity.
View Article and Find Full Text PDF